Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lung Kee Group Holdings's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 26.12.
Lung Kee Group Holdings's Days Inventory for the
six
months ended in Dec. 2025 was 334.28.
Lung Kee Group Holdings's Days Payable for the
six
months ended in Dec. 2025 was 98.61.
Therefore, Lung Kee Group Holdings's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 261.79.
Lung Kee Group Holdings (HKSE:00255) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Lung Kee Group Holdings Cash Conversion Cycle Related Terms
Lung Kee Group Holdings Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Lung Kee Group Holdings's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lung Kee Group Holdings Cash Conversion Cycle Chart
HKSE:00255 vs CRS, ATI, MLI: Cash Conversion Cycle Comparison
For the Metal Fabrication subindustry, Lung Kee Group Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lung Kee Group Holdings Cash Conversion Cycle vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Lung Kee Group Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Lung Kee Group Holdings's Cash Conversion Cycle falls into.
Lung Kee Group Holdings Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Lung Kee Group Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lung Kee Group Holdings (HKSE:00255) has a Cash Conversion Cycle of 261.79 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Lung Kee Group Holdings and its competitors.
Is Lung Kee Group Holdings' Cash Conversion Cycle too high?
Lung Kee Group Holdings' current Cash Conversion Cycle is 261.79. The Industrial Products industry median Cash Conversion Cycle is 121.69. Lung Kee Group Holdings' value of 261.79 is 115.1% above this industry median. Overall, Lung Kee Group Holdings has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lung Kee Group Holdings' Cash Conversion Cycle compare to CRS and ATI?
Lung Kee Group Holdings' Cash Conversion Cycle of 261.79 can be compared against companies in the Industrial Products industry. The industry median Cash Conversion Cycle is 121.69. Lung Kee Group Holdings' value of 261.79 is 115.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for an Industrial Products company?
The median Cash Conversion Cycle among Industrial Products companies is 121.69, based on 3,036 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lung Kee Group Holdings's current Cash Conversion Cycle of 261.79 is 115.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Lung Kee Group Holdings and its competitors. For the Industrial Products industry, the median Cash Conversion Cycle is 121.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lung Kee Group Holdings's current Cash Conversion Cycle is 261.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lung Kee Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lung Kee Group Holdings (HKSE:00255) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$1.24, compared to a current price of HK$1.50 — trading 20.6% above its estimated fair value. The current Cash Conversion Cycle is 261.79 and 115.1% above the Industrial Products industry median of 121.69. Lung Kee Group Holdings' overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Lung Kee Group Holdings (HKSE:00255), the current Cash Conversion Cycle is 261.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lung Kee Group Holdings (HKSE:00255) Overvalued in 2026?
Based on GuruFocus' analysis, Lung Kee Group Holdings stock appears to be overvalued.
The current stock price of HK$1.50 is trading 20.6% above its estimated GF Value™ of HK$1.24.
GuruFocus considers Lung Kee Group Holdings to be Modestly Overvalued.
Key valuation signals for HKSE:00255:
Cash Conversion Cycle: 261.79
GF Value™: HK$1.24 vs. price of HK$1.50 (20.6% above fair value)
Industry Position: 115.1% above the Industrial Products median
No single metric tells the full story. See the HKSE:00255 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lung Kee Group Holdings Ltd is an investment holding company that provides corporate management services. Along with its subsidiaries, it is engaged in the manufacturing and marketing of mould bases and related products. Its product offerings include standard and custom-made mould base, mould components, tool and steel products such as plastic and steel mould, hot and cold work steel, precision plates, standard mould inserts, and other materials. The company generates a majority of its revenue from the People's Republic of China and the rest from other markets like Asia, Europe, and America.
67GF Score
Get the complete analysis for HKSE:00255
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00255 has been successfully added to your 
